ImmuPharma Soars On Avion Lupus Deal
Validates Management Faith In Lupuzor
US speciality drugs group will fund the $25m costs of the UK company's new Phase III trial of Lupuzor, which has been much maligned by analysts.
US speciality drugs group will fund the $25m costs of the UK company's new Phase III trial of Lupuzor, which has been much maligned by analysts.